End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
39.38 CNY | -0.56% |
|
-0.83% | +12.48% |
08:39am | Sihuan Pharma Subsidiary Licenses Fadanafil Drug to Livzon Pharmaceutical Unit | MT |
Jun. 06 | Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company is one of the best yield companies with high dividend expectations.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.48% | 4.41B | B+ | ||
+48.79% | 781B | C+ | ||
+41.60% | 639B | B | ||
+19.43% | 330B | B- | ||
+7.18% | 293B | C+ | ||
+17.47% | 248B | B+ | ||
0.00% | 221B | A+ | ||
+11.51% | 217B | B- | ||
+4.53% | 162B | C+ | ||
-3.92% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000513 Stock
- Ratings Livzon Pharmaceutical Group Inc.